US Patent

US7939519 — Immunosuppresant compounds and compositions

Composition of Matter · Assigned to Novartis AG · Expires 2028-08-27 · 2y remaining

Vulnerability score 17/100 Ironclad — strong claim type, well-established, deep family

What this patent protects

This patent protects a novel class of immunosuppressant compounds useful in treating or preventing diseases mediated by lymphocyte interactions.

USPTO Abstract

The present invention relates to immunosuppressant, process for their production, their uses and pharmaceutical compositions containing them. The invention provides a novel class of compounds useful in the treatment or prevention of diseases or disorders mediated by lymphocyte interactions, particularly diseases associated with EDG receptor mediated signal transduction.

Drugs covered by this patent

Patent Metadata

Patent number
US7939519
Jurisdiction
US
Classification
Composition of Matter
Expires
2028-08-27
Drug substance claim
Yes
Drug product claim
Yes
Assignee
Novartis AG
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.